ArticleInfluenza and other respiratory viruses2026
Strengthening Respiratory Virus Surveillance in Sub-Saharan Africa: Integrated Epidemiological and Genomic Monitoring in Côte d'Ivoire.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update and optimization of a multiplex RT-qPCR assay to overcome diagnostic failure in emerging influenza A(H3N2) subclades J.2 and K (Peru, 2024-2026).IJID regions · 2026Article
- Strengthening Respiratory Virus Surveillance in Sub-Saharan Africa: Integrated Epidemiological and Genomic Monitoring in Côte d'Ivoire.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing WHO recommendations issued in 2019 and 2022, the National Influenza Center (NIC) of Côte d'Ivoire initiated the integration of Respiratory Syncytial Virus (RSV) and SARS-CoV-2 surveillance into its existing sentinel influenza surveillance to strengthen the monitoring of respiratory viruses.
methodsThe national influenza sentinel surveillance protocol was revised to include specific requirement of RSV and SARS-CoV-2. Nasopharyngeal swabs were collected between January 2022 and December 2023 for all three viruses and were tested by real time RT-PCR. Only PCR-positive samples with Ct value < 28 and adequate sample volume were selected for sequencing. CDC Flu SC2 multiplex rRT-PCR assay and Oxford Nanopore MinION Mk1C were used; influenza sequencing was performed at CDC Atlanta. Phylogenetic analyses were conducted to identify genotypes, lineages, and assess genetic relatedness to global strains.
resultsBetween January 2022 and December 2023, 8316 samples were tested; 12.6% (n = 1044) were positive for at least one of the three viruses. RSV (5.63%) detection in severe acute respiratory infection (SARI) cases increased significantly from 3.4% in 2022 to 8.4% in 2023 (p < 0.0001). Similarly, influenza (3.71%) detection in SARI cases rose from 1.3% to 2.6% (p = 0.0057). SARS-CoV-2 (3.22%) detection was significantly associated with age (p = 0.002). All three viruses circulated year-round with distinct seasonal peaks. Genomic analysis showed that A(H3N2) viruses belonged to clade 3C.2a1b.2a.2, A(H1N1) pdm09 to clade 6B.1A.5a.2 and B/Victoria to clade V1A.3a.2, all aligning with global trends. Among SARS-CoV-2 cases, BA.2 and BA.5 sublineages of Omicron predominated in 2022 while XBB and XBB.1.5 sublineages emerged in 2023. Whole genome sequencing revealed RSV A strains as genotype A.D.5.1 and RSV B as genotype B.D.E.1.
conclusionIntegration of RSV and SARS-CoV-2 into influenza sentinel surveillance has enabled continuous detection and genomic characterization, reinforcing the critical role of integrated sentinel surveillance for timely response to respiratory virus threats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.